Pasar al contenido principal

BASES MOLECULARES DEL CÁNCER

BES-2016-079096

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

  • Ballesteros-González, Irene
  • Hernández-Navas, Iván
  • Brehey, Oksana
  • Lechuga, Carmen G.
  • Salmón, Marina
  • Scotece, Morena
  • Velasco-Vicente, Ricardo
  • Flores-Gómez, Alejandra A.
  • Cebriá, Antonio
  • Simón-Carrasco, Lucía
  • Jiménez, Gerardo
  • Musteanu, Monica
  • Guerra, Carmen
  • Domínguez, Orlando
  • Caleiras, Eduardo
  • Blanco-Aparicio, Carmen
  • Pons, Tirso
  • Ferrer, Irene
  • Paz-Ares, Luis
  • Torres-Ruiz, Raul
  • Rodríguez-Perales, Sandra
  • Barbacid, Mariano
  • Drosten, Matthias
KRAS mutations are responsible for a quarter of all lung adenocarcinomas. However, the molecular mechanisms linking these mutations and their frequent secondary dosage amplification to tumor formation are still not fully understood. While ample evidence supports a crucial role for the MAPK pathway in tumor development, the primary effectors targeted by this pathway remain largely unexplored. Here we identify the transcriptional repressor Capicua (CIC) as a key target inactivated by KRAS/MAPK signaling in lung adenocarcinoma. We show that genetic loss of CIC recapitulates the phenotypic consequences of amplified KRAS signaling. Genetic disruption of CIC suppressed the requirement for Kras allelic imbalances and accelerated the transformation of bronchiolar Club cells. We also demonstrate that restoring CIC repressor activity impaired proliferation of CIC-deficient tumor cells and reverted resistance to MAPK pathway inhibitors. These results highlight the key role of CIC during lung tumor formation and suggest that selective pressure for effective CIC inactivation favors secondary amplification of KRAS/MAPK signaling in tumor cells., This work was supported by a grant from the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant PID2020-116705RB-I00) to M.D. M.D. also received funding from the Scientific Foundation of the Spanish Association Against Cancer (grant LABAE211678DROS). This work was further supported by a grant from the Scientific Foundation of the Spanish Association Against Cancer (Programa Excelencia 2022 grant EPAEC222641CICS); grants from Instituto de Salud Carlos III, co-funded by FEDER (grants PI23/01932 and PI21/01641) and the Scientific Foundation of the Spanish Association Against Cancer (grant LABAE20049RODR) to S.R.-P.; as well as a grant from the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant PID2020-119248GB-I00) to G.J. T.P. was supported in part by a grant from the Comunidad de Madrid (grant P2022/BMD-7321/MITIC-CM). This work was also supported in part by grants from the European Research Council (ERC-AG/695566 [THERACAN]), the Comunidad de Madrid (B2017/BMD-3884 iLUNG-CM) and the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (RTI2018-094664-B-I00) to M.B. M.B. is a recipient of an Endowed Chair from the AXA Research Fund. O.B. was a recipient of a fellowship from the Formación de Personal Investigador (FPI) program of the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (PRE2019-091685). M.Salmón was supported by a predoctoral contract “Severo Ochoa” from the Formación de Personal Investigador (FPI) program of the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (BES-2016-079096). A.A.F.-G. was a recipient of a CONAHCYT fellowship from the Mexican Government. L.S.-C. was supported by a Postdoctoral Research Contract from the Scientific Foundation of the Spanish Association Against Cancer (POSTD211274SIMÓ)., Peer reviewed